^
    Back
    Association details:
    Biomarker:NRAS mutation
    Cancer:Thyroid Gland Carcinoma
    Drug:Koselugo (selumetinib) (MEK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Comparing Complete Remission After Treatment With Selumetinib/Placebo in Patient With Differentiated Thyroid Cancer

    Excerpt:
    ...Complete Remission Rate (Expressed as Percentage of Patients in Complete Remission) at 18 Months Post-RAI Treatment; Subgroup Analysis BRAF/NRAS Mutation Positive`Clinical Remission Rate (Expressed as Percentage of Patients in Clinical Remission) at 18 Months Post-RAI Treatment; ITT Analysis Set`Clinical Remission Rate (Expressed as Percentage of Patients in Clinical Remission) at 18 Months Post-RAI Treatment; Subgroup Analysis BRAF/NRAS Mutation Positive...
    Trial ID:
    ASTRA
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    N Engl J Med
    Title:

    Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer

    Excerpt:
    Selumetinib produces clinically meaningful increases in iodine uptake and retention in a subgroup of patients with thyroid cancer that is refractory to radioiodine; the effectiveness may be greater in patients with RAS-mutant disease.
    DOI:
    10.1056/NEJMoa1209288